Sugi Predict

Sugi Predict / Compounds / SCHEMBL21248093

SCHEMBL21248093

SCHEMBL21248093

O=c1[nH]c(=O)c2cc(C(F)(F)F)ccc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.58
▸ KIF11 P52732 5/20 0.54
▸ KMT2A Q03164 3/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ CA12 O43570 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ PARP1 P09874 1/20 0.48
▸ PGR P06401 3/20 0.48
▸ CHUK O15111 1/20 0.47
▸ MAPT P10636 1/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14934160 0.88 PGR (0.50) KDM4EKIF11KMT2AMEN1CA12
SCHEMBL1458519 0.86 MAPT (0.57) KDM4EKIF11CA12CA9PARP1
SCHEMBL24576224 0.83 KDM4E (0.55) KDM4EKIF11KMT2AMEN1CA12
SCHEMBL2054576 0.82 KIF11 (0.54) KDM4EKIF11KMT2AMEN1CA12
SCHEMBL2417276 0.81 KMT2A (0.55) KDM4EKIF11KMT2AMEN1CA12
SCHEMBL30443527 0.81 KMT2A (0.55) KDM4EKIF11KMT2AMEN1CA12
SCHEMBL412032 0.78 KIF11 (0.81) KDM4EKIF11KMT2AMEN1CHUK
SCHEMBL29507666 0.78 KIF11 (0.81) KDM4EKIF11KMT2AMEN1CHUK
SCHEMBL21563889 0.77 KDM4E (0.57) KDM4EKIF11KMT2AMEN1CA12
SCHEMBL20885950 0.77 CA12 (0.45) KDM4EKIF11KMT2AMEN1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258354-B2 AhR modulators IDEAYA BIOSCIENCES, INC. (US) 2025-03-25 — — US disclosed
US-20250057958-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-02-20 — — US disclosed
EP-3749669-B3 AHR MODULATORS IDEAYA BIOSCIENCES INC (US) 2024-09-04 — — EP disclosed
CN-118496491-A Amino acid derived mimic enzyme organic catalyst and application thereof 青岛科技大学 2024-08-16 — — CN disclosed
CN-111683950-B AhR modulators 伊迪亚生物科学有限公司 2024-04-16 — — CN disclosed
EP-4347603-A1 SULFUR-CONTAINING HETEROAROMATIC TRICYCLIC KRAS INHIBITORS Erasca, Inc. (US) 2024-04-10 — — EP disclosed
US-20240051945-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF BLUEPRINT MEDICINES CORPORATION 2024-02-15 — — US disclosed
EP-4237418-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF Blueprint Medicines Corporation (US) 2023-09-06 — — EP disclosed
CN-116685583-A Pyrimidine compounds, compositions and pharmaceutical uses thereof 缆图药品公司 2023-09-01 — — CN disclosed
WO-2023161881-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-08-31 — — WO disclosed
US-20210002297-A1 AhR MODULATORS IDEAYA BIOSCIENCES, INC. 2021-01-07 — — US disclosed
US-20210002297-A1 AhR MODULATORS IDEAYA BIOSCIENCES, INC. 2021-01-07 — — US disclosed
EP-3749669-A1 AHR MODULATORS Ideaya Biosciences, Inc. (US) 2020-12-16 — — EP disclosed
US-10815250-B2 AhR modulators IDEAYA BIOSCIENCES, INC. (US) 2020-10-27 — — US disclosed
US-10815250-B2 AhR modulators IDEAYA BIOSCIENCES, INC. (US) 2020-10-27 — — US disclosed
CN-111683950-A AhR modulators 伊迪亚生物科学有限公司 2020-09-18 — — CN disclosed
US-20190270754-A1 AhR MODULATORS IDEAYA BIOSCIENCES, INC. 2019-09-05 — — US disclosed
US-20190270754-A1 AhR MODULATORS IDEAYA BIOSCIENCES, INC. 2019-09-05 — — US disclosed
WO-2019156987-A1 AhR MODULATORS IDEAYA BIOSCIENCES, INC. (US) 2019-08-15 — — WO disclosed
WO-2019156987-A1 AhR MODULATORS IDEAYA BIOSCIENCES, INC. (US) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051945-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF TYMP, DPYD, TYMS KDM4E 3754/4885KIF11 1537/4885KMT2A 3586/4885
US-20250057958-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS CCR2, CCR1, CCRL2 KDM4E 4709/4885KIF11 3412/4885KMT2A 3923/4885
US-12258354-B2 AhR modulators AHR, ARNT, RORB KDM4E 485/4885KIF11 4782/4885KMT2A 306/4885
US-10815250-B2 AhR modulators AHR, ARNT, RORB KDM4E 485/4885KIF11 4782/4885KMT2A 306/4885
US-20210002297-A1 AhR MODULATORS AHR, ARNT, RORB KDM4E 485/4885KIF11 4782/4885KMT2A 306/4885
US-20190270754-A1 AhR MODULATORS AHR, ARNT, RORB KDM4E 485/4885KIF11 4782/4885KMT2A 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.